MedTrace Logo

N-acetylcysteine for Tobacco Use Disorder

NCT02737358 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2020-08-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the effects of administering N-Acetylcysteine (NAC) to assist in initial cessation and/or relapse prevention in adult cigarette smokers.

Conditions

  • Nicotine Dependence
  • Smoking

Interventions

DRUG

N-acetylcysteine (NAC)

NAC or matched placebo will be given to study participants for 8 weeks.

OTHER

Placebo

Matched placebo (2 capsules taken in the morning and evening) will be taken by study participants for eight weeks. All participants will receive brief smoking cessation counseling and support.

Sponsors & Collaborators

  • Medical University of South Carolina

    lead OTHER

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-08-30
Primary Completion
2019-08-01
Completion
2019-10-10

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02737358 on ClinicalTrials.gov